Menu

Notable Science Quotes

Brexit's effect on science, melding disciplines, and more

Aug 1, 2016
The Scientist Staff

© ISTOCK.COM/ANDREW LINSCOTT

Being in the E.U. gives us access to ideas, people and to investment in science. That, combined with mobility [of EU scientists], gives us increased collaboration, increased transfer of people, ideas, and science—all of which history has shown us drives science.

—Nobel laureate Paul Nurse, director of the Francis Crick Institute and immediate past president of the Royal Society, speaking four months before UK citizens voted to leave the European Union in the historic “Brexit” referendum (BBC News, February 26)

 

For science to thrive it must have access to the single market, and we do need free movement. We could negotiate that outside the E.U., which will probably end up costing more money and we would have little influence [in deciding research priorities]. Or perhaps we should just reconsider this entire mess and see if there is something that can be done to reconsider this once the dust has settled.

Paul Nurse, on how the June 23 "Brexit" vote to leave the European Union could impact scientific research in the U.K. (BBC News, June 29)

 

Convergence has grown from a little seedling to a sprouting plant, but to become a great tree and orchard yielding fruit for decades into the future, it needs to be nourished, expanded, and cultivated now. Students need to be educated, collaborations need to be encouraged, and resources need to be committed to make sure convergence thrives.

—Nobel laureate Phillip Sharp, on the need to merge historically disparate disciplines, such as physics, computer science, mathematics, and the life sciences in order to achieve long-standing goals in biomedicine (MIT News, June 23)

 

By bringing together doctors and data like never before, precision medicine aims to deliver the right treatments in the right dosage at the right time—every time. It helps target the causes of a condition rather than just the symptoms. This is one of the greatest opportunities we’ve ever seen for new medical breakthroughs, but it only works if we collect enough information first.

—President Barack Obama, in a Boston Globe opinion piece about his administration’s efforts to make personalized medicine a broader reality (July 7)

 

Earth needs a virtual country: #Rationalia, with a one-line Constitution: All policy shall be based on the weight of evidence.

—Astrophysicist Neil deGrasse Tyson, in a recent tweet (June 29)

 

Tyson is a very smart man, but this is a very stupid tweet, and a very stupid idea. It is even, we might say, unreasonable and without sufficient evidence. Of course imagining a society in which all actors behave logically sounds appealing. But employing logic to consider the concept reveals that there could be no such thing.

Jeffrey Guhin, a University of California, Los Angeles, sociologist, criticizing Neil deGrasse Tyson’s controversial #Rationalia tweet (Slate, July 5)

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!